eligibility checklist

Funds Available

View the full list of funds available

Read more
eligibility checklist

What type of finance do I need?

Our online eligibility checklist helps you see which type of finance might be right for your business.

Read more
21 October 2015

Evgen Pharma plc – shares commence trading

Portfolio company admitted to AIM on the stock market

SPARK Impact Ltd is pleased to announce that Evgen Pharma plc, a portfolio company of the
North West Fund for Biomedical, has been admitted to the AIM market of the London Stock
Exchange and that its shares commence trading today.
Evgen Pharma plc, the Liverpool-based clinical stage drug development company whose lead
programmes are in breast cancer and subarachnoid haemorrhage (a type of stroke), raised £7m through an oversubscribed IPO. Its core technology is Sulforadex®, a means of synthesising and concurrently stabilising the naturally occurring compound sulforaphane (or novel analogues based upon it).
SPARK Impact first invested in Evgen Pharma via the North West Fund for Biomedical in 2011.
Dr Stephen Franklin, CEO of Evgen Pharma plc, said: "We thank both the North West Fund for
Biomedical and SPARK Impact for their support, which was pivotal in allowing Evgen Pharma to reach the stage where it was ready to join the public markets."
Dr Marc d'Abbadie, Investment Director at SPARK Impact, commenting on today's
announcement, said: "We are delighted with Evgen Pharma's progress, not least because of the value it has generated for the North West Fund for Biomedical but also because it provides yet more evidence of the quality of the science and entrepreneurs in the North West Biocluster."
Cliff Maylor, CEO at The North West Fund, said: "Evgen Pharma's oversubscribed IPO is a great example of the value that the North West Fund has delivered to the region by nurturing worldclass companies through the equity gap. We congratulate Evgen Pharma and look forward to seeing the company continue to grow."
The North West Fund for Biomedical is financed by the European Regional Development Fund
and the European Investment Bank.
ENDS

Back to article list